POPULARITY
89 episodes with bcacp
32 episodes with bcacp
21 episodes with bcacp
24 episodes with bcacp
14 episodes with bcacp
10 episodes with bcacp
8 episodes with bcacp
7 episodes with bcacp
15 episodes with bcacp
6 episodes with bcacp
7 episodes with bcacp
5 episodes with bcacp
5 episodes with bcacp
5 episodes with bcacp
4 episodes with bcacp
3 episodes with bcacp
3 episodes with bcacp
3 episodes with bcacp
Cardiovascular-Kidney-Metabolic (CKM) syndrome recognizes the interconnected relationship among cardiovascular disease, kidney disease, obesity, diabetes, and other metabolic risk factors that contribute to long-term health outcomes. The first-ever CKM clinical practice guideline introduces a framework for risk assessment, staging, prevention, and management, emphasizing early identification and coordinated care across disease states. You will be better prepared to recognize CKM syndrome, understand its implications for patient care, and support evidence-based strategies to reduce cardiovascular, kidney, and metabolic risk. HOSTRachel Maynard, PharmDGameChangers Podcast Host and Lead, Clinical & Partnership Education, CEimpactGUESTChristine Schumacher, PharmD, BCPS, BCACP, BCCP, BC-ADM, CDCES, FCCPProfessor, Pharmacy Practice and Clinical PharmacistMidwestern University Pharmacists, REDEEM YOUR CPE HERE!CPE is available to Health Mart franchise members onlyTo learn more about Health Mart, click here: https://join.healthmart.com/PRACTICE RESOURCEReceive the exclusive Practice Resource to use as a reference guide for this episode by enrolling in the course. Click here to enroll!CPE INFORMATION Learning ObjectivesUpon successful completion of this knowledge-based activity, participants should be able to:1. Describe the stages and key components of cardiovascular-kidney-metabolic syndrome.2. Explain evidence-based strategies for identifying and managing patients at risk for CKM syndrome.Christine Schumacher is a Speaker and Advisory Board Member for Abbott. All relevant financial relationships have been mitigated. 0.075 CEU/0.75 HrUAN: 0107-0000-26-315-H01-PInitial release date: 8/31/2026Expiration date: 8/31/2029Additional CPE details can be found here.
Cardiovascular-Kidney-Metabolic (CKM) syndrome recognizes the interconnected relationship among cardiovascular disease, kidney disease, obesity, diabetes, and other metabolic risk factors that contribute to long-term health outcomes. The first-ever CKM clinical practice guideline introduces a framework for risk assessment, staging, prevention, and management, emphasizing early identification and coordinated care across disease states. You will be better prepared to recognize CKM syndrome, understand its implications for patient care, and support evidence-based strategies to reduce cardiovascular, kidney, and metabolic risk.HOSTRachel Maynard, PharmDGameChangers Podcast Host and Lead, Clinical & Partnership Education, CEimpactGUESTChristine Schumacher, PharmD, BCPS, BCACP, BCCP, BC-ADM, CDCES, FCCPProfessor, Pharmacy Practice and Clinical PharmacistMidwestern UniversityGET CE FOR LISTENING!Stay Compliant. Grow Clinically. Practice with Confidence. Pharmacist CE Subscription: All your CE in one convenient subscription.All episodes, CE, and Practice Resources for the GameChangers Clinical Update is included with your Pharmacist CE Subscription. But wait…there's even more!The Pharmacist CE Subscription includes: - Compliance and licensure CE - GameChangers Clinical Updates- Practical continuing education across patient care topics *The subscription does not include microcredentials or certificates, which are available separately for pharmacists seeking specialized service training. Purchase Now!PRACTICE RESOURCEReceive the exclusive Practice Resource to use as a reference guide for this episode by purchasing the Pharmacist CE Subscription. CPE REDEMPTIONThis course is accredited for continuing pharmacy education! Click the link below that applies to you to take the exam and evaluation to claim credit:If you are already enrolled in this course, click here to redeem your credit. To purchase the Pharmacist CE Subscription and claim your CPE credit, click here or to purchase this course individually, click here. CPE INFORMATIONLearning ObjectivesUpon successful completion of this knowledge-based activity, participants should be able to:1. Describe the stages and key components of cardiovascular-kidney-metabolic syndrome.2. Explain evidence-based strategies for identifying and managing patients at risk for CKM syndrome.Christine Schumacher is a Speaker and Advisory Board Member for Abbott. All relevant financial relationships have been mitigated. 0.075 CEU/0.75 HrUAN: 0107-0000-26-315-H01-PInitial release date: 8/31/2026Expiration date: 8/31/2029Additional CPE details can be found here.Follow CEimpact on Social Media:LinkedInInstagram
What if your pharmacist could help optimize a patient's asthma treatment before their next clinic visit? On this episode of the BackTable ENT & Allergy Podcast, Dr. Basil Kahwash welcomes clinical pharmacist Dr. Joelle Ayoub to discuss how ambulatory care pharmacists can partner with ENT and allergy clinics to optimize asthma management. Dr. Ayoub shares her experience working in a family medicine clinic, collaborating with providers through referrals, reviewing medications, and providing direct patient education on inhaler use and disease management. --- Get the BackTable apphttps://www.backtable.com/app --- Timestamps 00:00 - Introduction02:40 - The Role of the Clinic Pharmacist05:04 - Teaching Patients and Improving Inhaler Technique12:36 - Choosing Inhalers and Applying Guidelines18:51 - Comparing MDI, DPI, and SMI Devices28:15 - Tracking Asthma Control and Monitoring Adherence33:55 - Inhaler Education and Overcoming Barriers40:00 - Using Social Media for Patient and Provider Education44:16 - Pharmacist Collaboration and the Future of Team Care50:58 - Answering Biologics Patient Questions53:15 - SMART Therapy and Digital Inhaler Advances55:19 - Wrap Up --- More about this episode They discuss common gaps in asthma care, with a focus on inhaler technique and medication adherence. Dr. Ayoub explains how device complexity, cost, and a patient's ability to use their inhaler can all affect treatment. She also reviews the major inhaler types, common technique errors, and what to consider when choosing the right device for each patient. With this, Dr. Ayoub shares practical approaches to adherence monitoring, asthma guideline updates, and biologic monitoring. Throughout, Dr. Ayoub emphasizes the benefits of multidisciplinary collaboration and how pharmacists can help bridge gaps in care for patients with asthma. --- Resources Joelle Ayoub, PharmD, BCACP, APh - https://www.westernu.edu/bios/?bio=jayoub --- BackTable ENT & Allergy is the go-to podcast for otolaryngologists, allergists, and head and neck surgeons. Download the free BackTable app to get early access to new episodes, cases, and courses curated by physicians in your specialty. ► https://www.backtable.com/app
Skin conditions are among the most common reasons patients seek advice from healthcare professionals, creating frequent opportunities for pharmacist intervention and support. This course reviews common dermatologic conditions encountered in pharmacy practice, including eczema, poison ivy, and other minor skin conditions and infections, while exploring the pharmacist's role in screening, triage, treatment selection, patient counseling, and prevention. You will be better prepared to support evidence-based management of common skin conditions and help patients access appropriate dermatologic care. HOSTRachel Maynard, PharmDGameChangers Podcast Host and Lead, Clinical & Partnership Education, CEimpactGUESTJamie McConaha, PharmD, BCACP, CDCES, FCCPAssociate Professor of Pharmacy PracticeDuquesne University School of Pharmacy Pharmacists, REDEEM YOUR CPE HERE!CPE is available to Health Mart franchise members onlyTo learn more about Health Mart, click here: https://join.healthmart.com/PRACTICE RESOURCEReceive the exclusive Practice Resource to use as a reference guide for this episode by enrolling in the course. Click here to enroll!CPE INFORMATION Learning ObjectivesUpon successful completion of this knowledge-based activity, participants should be able to:1. Describe clinical features and management considerations for common skin conditions encountered in pharmacy practice.2. Explain the pharmacist's role in screening, triage, treatment selection, patient counseling, and prevention of dermatologic conditions.Rachel Maynard and Jamie McConaha have no relevant financial relationships to disclose.0.05 CEU/0.5 HrUAN: 0107-0000-26-307-H01-P Initial release date: 8/10/2026Expiration date: 8/10/2029Additional CPE details can be found here.
Skin conditions are among the most common reasons patients seek advice from healthcare professionals, creating frequent opportunities for pharmacist intervention and support. This course reviews common dermatologic conditions encountered in pharmacy practice, including eczema, poison ivy, and other minor skin conditions and infections, while exploring the pharmacist's role in screening, triage, treatment selection, patient counseling, and prevention. You will be better prepared to support evidence-based management of common skin conditions and help patients access appropriate dermatologic care.HOSTRachel Maynard, PharmDGameChangers Podcast Host and Lead, Clinical & Partnership Education, CEimpactGUESTJamie McConaha, PharmD, BCACP, CDCES, FCCPAssociate Professor of Pharmacy PracticeDuquesne University School of PharmacyGET CE FOR LISTENING!Stay Compliant. Grow Clinically. Practice with Confidence. Pharmacist CE Subscription: All your CE in one convenient subscription.All episodes, CE, and Practice Resources for the GameChangers Clinical Update is included with your Pharmacist CE Subscription. But wait…there's even more!The Pharmacist CE Subscription includes: - Compliance and licensure CE - GameChangers Clinical Updates- Practical continuing education across patient care topics *The subscription does not include microcredentials or certificates, which are available separately for pharmacists seeking specialized service training. Purchase Now!PRACTICE RESOURCEReceive the exclusive Practice Resource to use as a reference guide for this episode by purchasing the Pharmacist CE Subscription. CPE REDEMPTIONThis course is accredited for continuing pharmacy education! Click the link below that applies to you to take the exam and evaluation to claim credit:If you are already enrolled in this course, click here to redeem your credit. To purchase the Pharmacist CE Subscription and claim your CPE credit, click here or to purchase this course individually, click here. CPE INFORMATIONLearning ObjectivesUpon successful completion of this knowledge-based activity, participants should be able to:1. Describe clinical features and management considerations for common skin conditions encountered in pharmacy practice.2. Explain the pharmacist's role in screening, triage, treatment selection, patient counseling, and prevention of dermatologic conditions.Rachel Maynard and Jamie McConaha have no relevant financial relationships to disclose.0.05 CEU/0.5 HrUAN: 0107-0000-26-307-H01-P Initial release date: 8/10/2026Expiration date: 8/10/2027Additional CPE details can be found here.Follow CEimpact on Social Media:LinkedInInstagram
In this episode of Mind the Meds, host Erica Marini, PharmD, MS, BCPS, welcomes Jenelle Hall Montgomery, PharmD, BCACP, CPP, a clinical pharmacist practitioner with Duke Neurological Disorders Clinic at Duke University Hospital, to discuss highlights from the Consortium of Multiple Sclerosis Centers (CMSC) Annual Meeting in Charlotte, North Carolina, where Montgomery was recognized as a Giant of Multiple Sclerosis. Before the CMSC discussion, Marini runs through a roundup of recent neurology news, including approval of at-home initiation dosing for lecanemab-irmb (Leqembi; Eisai, Biogen), fast track designation for remlifanserin (Acadia Pharmaceuticals) in Alzheimer disease psychosis, approval of the oral PCSK9 inhibitor enlicitide (Lipfendra; Merck), and phase 3 data on tavapadon (AbbVie) for Parkinson disease showing a lower rate of impulse control disorders than traditional dopamine agonists.The pharmacists then turn to CMSC sessions on off-label and evolving areas of MS care. They discuss growing interest in neurofilament light chain as a biomarker for tracking subclinical disease progression over time, along with the ongoing debate over when it is safe to discontinue disease-modifying therapy (DMT) in older, stable patients. Both note their practices generally begin this conversation around 60 to 65 years of age, factoring in radiographic and clinical stability over the preceding decade, and describe strategies such as tapering dosing frequency or switching to lower-efficacy agents rather than abrupt discontinuation.The conversation closes with an update on family planning in MS, where new data presented at CMSC reinforce the safety of anti-CD20 therapies during pregnancy and breastfeeding. Montgomery and Marini review a 10-year dataset of about 5000 pregnancies on ocrelizumab (Ocrevus; Genentech), a large safety analysis of ofatumumab (Kesimpta; Novartis Pharmaceuticals) showing no increase in birth malformations, and early transfer-into-breastmilk data on ublituximab (Briumvi; TG Therapeutics). They also touch on the limited but growing evidence for GLP-1 receptor agonists in patients with MS, noting no known drug interactions with DMTs and possible indirect benefit through weight-related disease modulation, though neither pharmacist currently prescribes GLP-1s for an MS indication.Key Takeaways:1. Neurofilament light chain is emerging as a useful, though not yet mainstream, biomarker in MS. Rather than a single value, tracking neurofilament light chain over time alongside clinical status may help identify subclinical disease progression, particularly in patients without clear relapses.2. DMT discontinuation in older, stable patients remains individualized, with most practices starting the conversation around 60 to 65 years of age. Clinicians weigh 10-year clinical and radiographic stability, and some patients opt for a gradual step-down in dosing frequency or a switch to a lower-efficacy agent rather than outright discontinuation.3. New pregnancy and breastfeeding safety data continue to support anti-CD20 therapies as a preferred family planning strategy in MS. A 10-year, 5000-pregnancy dataset on ocrelizumab, reassuring malformation data on ofatumumab, and early breastmilk transfer data on ublituximab are strengthening patient counseling conversations around conception, pregnancy, and postpartum DMT resumption.
At the 2026 National ICE-T Conference in Orlando, CancerNetwork® sat down with a variety of expert researchers and clinicians to discuss the latest developments in immune effector therapy across different hematologic oncology populations. Sessions at the meeting covered practical considerations for integrating CAR T-cell therapies, bispecific antibodies, and other modalities into the treatment of those with multiple myeloma, lymphoma, and other hematologic malignancies.First, Benjamin Diamond, MD, an assistant professor of Clinical Medicine, a member of the Sylvester Myeloma Institute, and a member of the Myeloma Genomic Lab at the University of Miami Miller School of Medicine, spoke about his presentation reviewing bispecific antibodies for the management of multiple myeloma. In his session, Diamond stated that bispecific T-cell engagers are altering the landscape of multiple myeloma care and will eventually become an option in the frontline setting. With many products to choose from, Diamond emphasized sequencing these novel therapies wisely and stressed aggressive infection prophylaxis as a mandatory facet of care.Next, Tiba Al Sagheer, PharmD, BCOP, BCACP, a pharmacy quality improvement coordinator for transplant and cellular therapy at Miami Cancer Institute of Baptist Health South Florida discussed her presentation focused on defining new thresholds for monitoring and mitigating toxicities associated with CAR T-cell therapy. She described considerations for balancing early toxicity intervention against the risk of blunting efficacy depending on the specific CAR T-cell product used during treatment. Ultimately, she noted that that there is still no definitive answer or threshold for initiating prophylaxis for toxicity associated with CAR T, and that differentiating between immune effector cell (IEC)–associated hemophagocytic lymphohistiocytosis (HLH)–like syndrome (IEC-HS) and cytokine release syndrome (CRS) represents an ongoing challenge in the field.Finally, Nikesh N. Shah, MD, and Carlos Silva Rondon, MD, shared their perspectives on a debate regarding the roles of bispecific antibodies and CAR T-cell therapies in relapsed/refractory follicular lymphoma. In his presentation, Shah, a hematologist-oncologist at Tampa General Hospital who specializes in hematologic malignancies, including aggressive lymphomas and acute lymphoblastic leukemia, took the position that bispecific antibodies should be used prior to CAR T-cell therapy for most patients, although both treatments have utility in the field. Silva Rondon, a hematologist, oncologist, and bone marrow transplant specialist at Moffitt Malignant Hematology and Cellular Therapy at Memorial Healthcare System/Memorial Cancer Institute in Pembroke Pines, advocated for CAR T-cell therapy during the debate but acknowledged that both modalities can make up a complementary strategy for overcoming relapsed/refractory follicular lymphoma.References Diamond B. Bispecific antibodies for the management of multiple myeloma. Presented at the 2026 National ICE-T Conference; July 18, 2026; Orlando, FL. Sagheer TA. Thresholds and therapeutics: a precision approach to CAR T toxicity management. Presented at the 2026 National ICE-T Conference; July 18, 2026; Orlando, FL. Shah N. Debate: bispecific antibodies vs CAR-T in follicular lymphoma. Presented at the 2026 National ICE-T Conference; July 18, 2026; Orlando, FL. Silva C. CAR-T cell therapy for relapsed follicular lymphoma. Presented at the 2026 National ICE-T Conference; July 18, 2026; Orlando, FL.
On this episode of IPA's What, Why & How podcast, IPA's Vice President of Professional Affairs, Brian Wall, sits down with Iowa Board of Pharmacy Chair Erik Maki and Vice Chair Connie Connolly to discuss public service, meaningful engagement in the regulatory process, and key takeaways from the Board's July meeting. Listeners will gain a clearer understanding of how the Board, state lawmakers, IPA, and pharmacy professionals each contribute to advancing safe and effective pharmacy practice in Iowa. Erik Maki, PharmD, BCPS, serves as Dean of the College of Pharmacy and Health Sciences and as a Professor of Pharmacy Practice at Drake University. Erik grew up in Iowa City, where he also received his Doctor of Pharmacy degree and met his wife, Jenifer. After completing residency at Texas Tech University, Erik came to Drake to work with wonderful people who shared a commitment to student success through teaching excellence, cultivation of meaningful personal relationships, and mentoring. Erik has held a variety of departmental, college, and university leadership roles, including services as the Chair of the University IRB and an elected representative on the faculty senate. Prior to serving as Dean, Erik was the Chair of the Pharmacy Practice Department. He is currently serving his second term on the Iowa Board of Pharmacy. Connie Connolly, BS Pharm, BCACP, attended pharmacy school at the University of Iowa College of Pharmacy. She has practiced at Osterhaus Pharmacy in Maquoketa, IA, for over twenty years and has precepted student pharmacists at Drake University and the University of Iowa for even longer. Connie served as President of the Iowa Pharmacy Association from 2019-2020 and currently serves on the IPA Foundation Board of Directors. She is serving her second term on the Iowa Board of Pharmacy. More Information: Iowa Board of Pharmacy Newsletter Signup Iowa Board of Pharmacy Meeting Schedule, Agendas & Minutes Contact the Iowa Board of Pharmacy: ibp@dial.iowa.org “I'm Just a Bill” – Schoolhouse Rock Iowa Pharmacy Law & Information Resource Center (LIRC) Connect with us on LinkedIn: Erik Maki Connie Connolly Brian Wall Iowa Pharmacy Association
What happens when learners teach learners? Layered learning is a teaching model that brings pharmacy students, residents, and preceptors together in a collaborative learning environment. Our host Carolyn Liptak is joined by Dr. Sarah Eggers Russell, PharmD, BCACP, CPP of UNC Health REX and Dr. Kimberly James, PharmD of UF Health to discuss how layered learning works in pharmacy residency programs and why it continues to gain traction across healthcare settings. They share perspectives from their own programs and discuss what it takes to create meaningful learning experiences for learners at every stage of training. Guest Speakers: Dr. Sarah Eggers Russell, PharmD, BCACP, CPP UNC Health REX Dr. Kimberly James, PharmD UF Health Host: Carolyn Liptak, MBA, BS Pharm Pharmacy Executive Director, Regulatory Compliance Vizient Center for Pharmacy Practice Excellence Show Notes: 00:05 - What Is Layered Learning? Definition of layered learning and its role in pharmacy education How teaching, mentorship, and patient care occur simultaneously Benefits for learners, preceptors, and patients 01:08 - Residency Program Overviews UNC Health Rex ambulatory care residency program UF Health pediatric pharmacy residency program Opportunities for students, residents, and advanced learners across diverse practice settings 02:22 - How Layered Learning Works in Practice Senior learners mentoring junior learners under pharmacist supervision Developing teaching skills and professional behaviors Expanding direct patient care opportunities while supporting preceptor workloads 03:33 - Defining Roles and Responsibilities Setting expectations before the rotation begins Assessing learner readiness for teaching responsibilities Creating structured orientation processes for all learners Providing feedback and evaluation opportunities for resident preceptors 05:55 - Adapting to Different Learning Styles Tailoring rotations to individual learner needs Gradually increasing clinical responsibilities Using regular feedback sessions and midpoint evaluations Building confidence through progressive independence 08:20 - Building Successful Layered Learning Experiences Differences between primary and co precepting models Leveraging learners to expand patient access and clinical services Using shared precepting across diverse practice environments Creating opportunities for leadership and teaching development 10:42 - Keeping Learners Engaged in Ambulatory Care Managing clinic schedules and patient encounters Evidence based patient case presentations Topic discussions, drug information requests, and interdisciplinary shadowing opportunities Exposure to diagnostic testing and specialty practice areas 12:13 - Structuring Layered Learning in the Inpatient Setting Working across multiple specialty consult services Presenting to interdisciplinary healthcare teams Shadowing opportunities with nursing and other disciplines Using projects to improve patient care and learner engagement 13:39 - Advice for First Time Preceptors Maintaining flexibility and adaptability Meeting learners where they are in their development Keeping communication open through regular check ins Encouraging learners to embrace new challenges and teaching opportunities 14:51 - The Lasting Impact of Layered Learning Benefits for junior learners, advanced learners, and preceptors Strengthening interdisciplinary collaboration Increasing awareness of pharmacy residency programs Bringing fresh perspectives and new ideas into clinical practice 16:34 - Resources and What's Next ASHP Guide for Best Practices of Layered Learning Upcoming Vizient Layered Learning Toolkit currently in development Links and Resources: Residency-Guide_Best-Practices-for-Resident-Engagement-in-LLM_Final.ashx Subscribe Today! Apple Podcasts Spotify YouTube RSS Feed
Acute rescue medications are critical in time-sensitive emergencies, and pharmacists play an essential role in ensuring patients and caregivers are prepared to use them correctly. This course discusses the roles of glucagon, naloxone, and epinephrine, including recent updates on novel formulations and device innovations that are reshaping emergency response in community settings. You will gain practical insights to strengthen counseling, improve readiness, and support optimal outcomes when seconds matter most. HOST Rachel Maynard, PharmD GameChangers Podcast Host and Lead, Clinical & Partnership Education, CEimpactGUESTWendy Mobley-Bukstein, PharmD, BCACP, CDCES, CHWC, NASM-CPTProfessor of Pharmacy PracticeDrake University CPHS Pharmacists, REDEEM YOUR CPE HERE!CPE is available to Health Mart franchise members onlyTo learn more about Health Mart, click here: https://join.healthmart.com/PRACTICE RESOURCEReceive the exclusive Practice Resource to use as a reference guide for this episode by enrolling in the course. Click here to enroll!CPE INFORMATION Learning ObjectivesUpon successful completion of this knowledge-based activity, participants should be able to:1. Describe the mechanisms of action and primary indications for glucagon, naloxone, and epinephrine as acute rescue medications.2. Summarize recent updates for glucagon, naloxone, and epinephrine that impact pharmacist counseling and patient access.Rachel Maynard has no relevant financial relationships with ineligible companies to disclose. Wendy Mobley-Bukstein is a Diabetes Care Speaker for Abbott. All relevant financial relationships have been mitigated. 0.05 CEU/0.5 HrUAN: 0107-0000-26-131-H01-P Initial release date: 5/18/2026Expiration date: 5/18/2027Additional CPE details can be found here.
Acute rescue medications are critical in time-sensitive emergencies, and pharmacists play an essential role in ensuring patients and caregivers are prepared to use them correctly. This course discusses the roles of glucagon, naloxone, and epinephrine, including recent updates on novel formulations and device innovations that are reshaping emergency response in community settings. You will gain practical insights to strengthen counseling, improve readiness, and support optimal outcomes when seconds matter most.HOSTRachel Maynard, PharmD GameChangers Podcast Host and Lead, Clinical & Partnership Education, CEimpactGUESTWendy Mobley-Bukstein, PharmD, BCACP, CDCES, CHWC, NASM-CPTProfessor of Pharmacy PracticeDrake University CPHSGET CE FOR LISTENING!Stay Compliant. Grow Clinically. Practice with Confidence. Pharmacist CE Subscription: All your CE in one convenient subscription.All episodes, CE, and Practice Resources for the GameChangers Clinical Update is included with your Pharmacist CE Subscription. But wait…there's even more!The Pharmacist CE Subscription includes: - Compliance and licensure CE - GameChangers Clinical Updates- Practical continuing education across patient care topics *The subscription does not include microcredentials or certificates, which are available separately for pharmacists seeking specialized service training. Purchase Now!PRACTICE RESOURCEReceive the exclusive Practice Resource to use as a reference guide for this episode by purchasing the Pharmacist CE Subscription.CPE REDEMPTIONThis course is accredited for continuing pharmacy education! Click the link below that applies to you to take the exam and evaluation to claim credit:If you are already enrolled in this course, click here to redeem your credit. To purchase the Pharmacist CE Subscription and claim your CPE credit, click here or to purchase this course individually, click here. CPE INFORMATIONLearning ObjectivesUpon successful completion of this knowledge-based activity, participants should be able to:1. Describe the mechanisms of action and primary indications for glucagon, naloxone, and epinephrine as acute rescue medications.2. Summarize recent updates for glucagon, naloxone, and epinephrine that impact pharmacist counseling and patient access.Rachel Maynard has no relevant financial relationships with ineligible companies to disclose. Wendy Mobley-Bukstein is a Diabetes Care Speaker for Abbott. All relevant financial relationships have been mitigated. 0.05 CEU/0.5 HrUAN: 0107-0000-26-131-H01-P Initial release date: 5/18/2026Expiration date: 5/18/2027Additional CPE details can be found here.Follow CEimpact on Social Media:LinkedInInstagram
This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/CPE/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/QVU865. CME/CPE/AAPA/IPCE credit will be available until April 25, 2027.B-Keepers: Pharmacist Principles for Effective BTK Targeting in CLL, MCL, and Other B-Cell Cancers In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by independent educational grants from AstraZeneca, BeOne Medicines, and Lilly.Disclosure information is available at the beginning of the video presentation.
This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/CPE/IPCE information, and to apply for credit, please visit us at PeerView.com/BGR865. CME/MOC/CPE/IPCE credit will be available until May 1, 2027.Coordinating Transformative Care in NHL: Pharmacist Insights for Delivering CAR-T Therapy in the Era of Expanded Access and Therapeutic Innovation In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported through independent educational grants from Bristol Myers Squibb and Novartis Pharmaceuticals Corporation.Disclosure information is available at the beginning of the video presentation.
This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/CPE/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/QVU865. CME/CPE/AAPA/IPCE credit will be available until April 25, 2027.B-Keepers: Pharmacist Principles for Effective BTK Targeting in CLL, MCL, and Other B-Cell Cancers In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by independent educational grants from AstraZeneca, BeOne Medicines, and Lilly.Disclosure information is available at the beginning of the video presentation.
This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/CPE/IPCE information, and to apply for credit, please visit us at PeerView.com/BGR865. CME/MOC/CPE/IPCE credit will be available until May 1, 2027.Coordinating Transformative Care in NHL: Pharmacist Insights for Delivering CAR-T Therapy in the Era of Expanded Access and Therapeutic Innovation In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported through independent educational grants from Bristol Myers Squibb and Novartis Pharmaceuticals Corporation.Disclosure information is available at the beginning of the video presentation.
This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/CPE/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/QVU865. CME/CPE/AAPA/IPCE credit will be available until April 25, 2027.B-Keepers: Pharmacist Principles for Effective BTK Targeting in CLL, MCL, and Other B-Cell Cancers In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by independent educational grants from AstraZeneca, BeOne Medicines, and Lilly.Disclosure information is available at the beginning of the video presentation.
This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/CPE/IPCE information, and to apply for credit, please visit us at PeerView.com/BGR865. CME/MOC/CPE/IPCE credit will be available until May 1, 2027.Coordinating Transformative Care in NHL: Pharmacist Insights for Delivering CAR-T Therapy in the Era of Expanded Access and Therapeutic Innovation In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported through independent educational grants from Bristol Myers Squibb and Novartis Pharmaceuticals Corporation.Disclosure information is available at the beginning of the video presentation.
This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/CPE/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/QVU865. CME/CPE/AAPA/IPCE credit will be available until April 25, 2027.B-Keepers: Pharmacist Principles for Effective BTK Targeting in CLL, MCL, and Other B-Cell Cancers In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by independent educational grants from AstraZeneca, BeOne Medicines, and Lilly.Disclosure information is available at the beginning of the video presentation.
This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/CPE/IPCE information, and to apply for credit, please visit us at PeerView.com/BGR865. CME/MOC/CPE/IPCE credit will be available until May 1, 2027.Coordinating Transformative Care in NHL: Pharmacist Insights for Delivering CAR-T Therapy in the Era of Expanded Access and Therapeutic Innovation In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported through independent educational grants from Bristol Myers Squibb and Novartis Pharmaceuticals Corporation.Disclosure information is available at the beginning of the video presentation.
This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/CPE/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/QVU865. CME/CPE/AAPA/IPCE credit will be available until April 25, 2027.B-Keepers: Pharmacist Principles for Effective BTK Targeting in CLL, MCL, and Other B-Cell Cancers In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by independent educational grants from AstraZeneca, BeOne Medicines, and Lilly.Disclosure information is available at the beginning of the video presentation.
This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/CPE/IPCE information, and to apply for credit, please visit us at PeerView.com/BGR865. CME/MOC/CPE/IPCE credit will be available until May 1, 2027.Coordinating Transformative Care in NHL: Pharmacist Insights for Delivering CAR-T Therapy in the Era of Expanded Access and Therapeutic Innovation In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported through independent educational grants from Bristol Myers Squibb and Novartis Pharmaceuticals Corporation.Disclosure information is available at the beginning of the video presentation.
This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/CPE/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/QVU865. CME/CPE/AAPA/IPCE credit will be available until April 25, 2027.B-Keepers: Pharmacist Principles for Effective BTK Targeting in CLL, MCL, and Other B-Cell Cancers In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by independent educational grants from AstraZeneca, BeOne Medicines, and Lilly.Disclosure information is available at the beginning of the video presentation.
This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/CPE/IPCE information, and to apply for credit, please visit us at PeerView.com/BGR865. CME/MOC/CPE/IPCE credit will be available until May 1, 2027.Coordinating Transformative Care in NHL: Pharmacist Insights for Delivering CAR-T Therapy in the Era of Expanded Access and Therapeutic Innovation In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported through independent educational grants from Bristol Myers Squibb and Novartis Pharmaceuticals Corporation.Disclosure information is available at the beginning of the video presentation.
Listen in as our expert panel covers the latest evidence on using menopausal hormone therapy and nonhormonal options for treatment of vasomotor symptoms (hot flashes, etc). You'll also hear experts discuss treatments for genitourinary symptoms (vaginal dryness, etc) as well as low libido and brain fog.Special guests:Veronica Vernon, PharmD, BCPS, BCACP, MSCP, FAPhA Associate Professor, Chair of Pharmacy PracticeButler UniversitySarah M. Westberg, PharmD, FCCP, BCPSAssociate Dean for Professional Affairs Professor, College of PharmacyUniversity of MinnesotaYou'll also hear practical advice from panelists on TRC's Editorial Advisory Board:Andrea Darby-Stewart, MDAssociate Director, Honor Health Family Medicine Residency ProgramClinical Professor of Family, Community & Occupational MedicineThe University of Arizona College of Medicine – PhoenixCraig D. Williams, PharmD, FNLA, BCPSClinical Professor of Pharmacy PracticeOregon Health and Science UniversityNone of the speakers have anything to disclose. This podcast is an excerpt from one of TRC's monthly live CE webinars, the full webinar originally aired in March 2026.
Advancements in hypertension management are shifting the landscape of treatment, from new guideline recommendations to technological innovations. This course explores key highlights from the AHA's recent scientific statements, including single-pill combination therapy and the clinical limitations of some blood pressure devices, alongside updates to the 2025 hypertension guidelines. You will gain a clear understanding of how these changes affect patient care, medication strategies, and pharmacist-driven interventions.Recent ACC/AHA Cholesterol Guidelines further emphasize comprehensive cardiovascular risk assessment and evidence-based management of dyslipidemia alongside other major risk factors such as hypertension. These updates complement the hypertension topics discussed in this episode by reinforcing the importance of coordinated, risk-based approaches to reducing cardiovascular disease. This resource provides a concise, guideline-based overview of hypertension management, summarizing the 2025 ACC/AHA recommendations for blood pressure classification, treatment goals, and stepwise pharmacotherapy. It highlights first- and second-line antihypertensive options, emphasizes individualized, risk-based treatment decisions, and outlines practical considerations for therapy initiation, intensification, and monitoring to optimize cardiovascular outcomes.HOSTRachel Maynard, PharmDGameChangers Podcast Host and Clinical Editor, CEimpactLead Editor, PyrlsGUESTTomasz Jurga, PharmD, BCPS, BCACP, BCCP, HF-Cert, CDCES, AACCClinical Pharmacist PractitionerLTC Charles S. Kettles VA Medical CenterPharmacists, REDEEM YOUR CPE HERE!CPE is available to Health Mart franchise members onlyTo learn more about Health Mart, click here: https://join.healthmart.com/PRACTICE RESOURCEReceive the exclusive Practice Resource to use as a reference guide for this episode by enrolling in the course. Click here to enroll!CPE INFORMATIONLearning ObjectivesUpon successful completion of this knowledge-based activity, participants should be able to:1. Identify recent guideline and practice updates that may influence the diagnosis, treatment, and monitoring of hypertension.2. Discuss current and emerging tools and strategies that support safe, effective, and individualized hypertension management.Rachel Maynard has no relevant financial relationships with ineligible companies to disclose. Tomasz Jurga has disclosed that a grant from Merck supported Pharmacy Times Continuing Education activities, including speaking honoraria. All relevant financial relationships have been mitigated.0.1 CEU/1.0 HrUAN: 0107-0000-26-073-H01-PInitial release date: 4/6/2026Expiration date: 4/6/2027Additional CPE details can be found here.
Advancements in hypertension management are shifting the landscape of treatment, from new guideline recommendations to technological innovations. This course explores key highlights from the AHA's recent scientific statements, including single-pill combination therapy and the clinical limitations of some blood pressure devices, alongside updates to the 2025 hypertension guidelines. You will gain a clear understanding of how these changes affect patient care, medication strategies, and pharmacist-driven interventions.Recent ACC/AHA Cholesterol Guidelines further emphasize comprehensive cardiovascular risk assessment and evidence-based management of dyslipidemia alongside other major risk factors such as hypertension. These updates complement the hypertension topics discussed in this episode by reinforcing the importance of coordinated, risk-based approaches to reducing cardiovascular disease.This resource provides a concise, guideline-based overview of hypertension management, summarizing the 2025 ACC/AHA recommendations for blood pressure classification, treatment goals, and stepwise pharmacotherapy. It highlights first- and second-line antihypertensive options, emphasizes individualized, risk-based treatment decisions, and outlines practical considerations for therapy initiation, intensification, and monitoring to optimize cardiovascular outcomes.HOSTRachel Maynard, PharmDGameChangers Podcast Host and Clinical Editor, CEimpactLead Editor, PyrlsGUESTTomasz Jurga, PharmD, BCPS, BCACP, BCCP, HF-Cert, CDCES, AACCClinical Pharmacist PractitionerLTC Charles S. Kettles VA Medical CenterGET CE FOR THIS LISTENING!The GameChangers Clinical Update Series for Pharmacists delivers 52 expert-led podcast episodes and 30+ hours of clinically actionable continuing education, all for a one-time purchase of just $99—that's less than $3 per hour for high-impact learning you can apply immediately in practice. Click here to enroll. PRACTICE RESOURCEReceive the exclusive Practice Resource to use as a reference guide for this episode by purchasing the GameChangers Clinical Update Series. CPE REDEMPTIONThis course is accredited for continuing pharmacy education! Click the link below that applies to you to take the exam and evaluation to claim credit:If you are already enrolled in this course, click here to redeem your credit. To purchase the Clinical Update Series and claim your CPE credit, click here or to purchase this course individually, click here. CPE INFORMATIONLearning ObjectivesUpon successful completion of this knowledge-based activity, participants should be able to:1. Identify recent guideline and practice updates that may influence the diagnosis, treatment, and monitoring of hypertension.2. Discuss current and emerging tools Follow CEimpact on Social Media:LinkedInInstagram
Listen in as our expert panel tackles real-world questions about GLP-1 agonists, from starting them and setting expectations with patients to strategies for switching agents. You'll also hear them review key considerations to limit muscle loss with GLP-1 agonist use and discuss why some patients hit a plateau or don't respond to GLP-1 agonists.Special guests:Jennifer N. Clements, PharmD, FCCP, FADCES, BCPS, BCACP, CDCES, BC-ADMClinical Professor and Director of Pharmacy EducationUniversity of South Carolina College of PharmacyJennifer M. Trujillo, PharmD, BCPS, FCCP, CDCES, BC-ADMProfessor and the Associate Dean for EducationUniversity of Colorado Skaggs School of Pharmacy and Pharmaceutical SciencesPanelists on TRC's Editorial Advisory Board:Stephen Carek, MD, CAQSM, DipABLMClinical Associate Professor of Family MedicinePrisma Health/USC-SOMG Family Medicine Residency ProgramUSC School of Medicine GreenvilleCraig D. Williams, PharmD, FNLA, BCPSClinical Professor of Pharmacy PracticeOregon Health and Science UniversityFor the purposes of disclosure Dr. Jennifer Clements reports relevant financial relationships with Novo Nordisk (Ozempic, Rybelsus), Eli Lilly (Zepbound, tirzepatide) [speakers bureau].The other speakers have nothing to disclose. All relevant financial relationships have been mitigated.This podcast is an excerpt from one of TRC's monthly live CE webinars, the full webinar originally aired in February 2026.
It's In the News, a look at the top headlines and stories in the diabetes community. This week's top stories: Metformin may help stem macular degeneration, retatutride moves forward, T1D and demntia link studied, lots of news from ATTD and more! Announcing Community Commericals! Learn how to get your message on the show here. Learn more about studies and research at Thrivable here Please visit our Sponsors & Partners - they help make the show possible! Omnipod - Simplify Life All about Dexcom All about VIVI Cap to protect your insulin from extreme temperatures The best way to keep up with Stacey and the show is by signing up for our weekly newsletter: Sign up for our newsletter here Here's where to find us: Facebook (Group) Facebook (Page) Instagram Check out Stacey's books! Learn more about everything at our home page www.diabetes-connections.com transcript with links: Welcome! I'm your host Stacey Simms and this is an In The News episode.. where we bringing you the top diabetes stories and headlines happening now. A reminder that you can find the sources and links and a transcript and more info for every story mentioned here in the show notes. Who's in Vegas? I'll see you there at the Breakthrough T1D summit this weekend. And we have two Club 1921 events for health care providers and patient leaders happening in April – head on over to the website for more. Okay.. our top story this week: XX Metformin may be linked to the slower progression of age-related macular degeneration (AMD). Among people with diabetes who were older than 55, those taking metformin had a 37% lower chance of developing intermediate AMD over a five-year period compared with individuals who were not using the medication. It's one of the leading causes of vision loss in the US and many other western countries. These researchers now say a clinical trial is the next step. https://scitechdaily.com/scientists-discover-surprising-eye-benefit-of-widely-used-diabetes-drug/ XX new study suggests people with type 1 diabetes may be nearly three times as likely to develop dementia compared with people without diabetes. Similarly, people with type 2 diabetes may have roughly twice the risk of dementia compared with those without diabetes. However, the study found an association rather than proof of causation, meaning diabetes was linked to dementia risk but was not shown to directly cause it. https://www.usnews.com/news/health-news/articles/2026-03-19/both-types-of-diabetes-increase-dementia-risk XX Researchers in Japan say they've developed an insulin pill… in mice. The study, published in the journal Molecular Pharmaceutics, tested the delivery of oral insulin by building a carrier peptide called DNP-V. This peptide helps to transport insulin through the small intestine, where protein drug absorption is usually poor. The result was a rapid and significant drop in blood glucose, as well as a sustained (longer-term) decrease. The mice's blood sugar was reduced to near-normal levels. Although the researchers are optimistic about the findings translating to larger therapeutic models, they noted that the results in mice do not guarantee the same outcome in humans, and that more research is needed. https://www.foxnews.com/health/needle-free-diabetes-management-could-horizon-study-suggests XX Lilly says it's next-generation obesity drug retatutride cleared its first late-stage trial on Type 2 diabetes patients. The drug lowered hemoglobin A1C by an average of 1.7% to 2% across different doses at 40 weeks compared with placebo, and helped patients lose an average of 16.8% of their weight. Retatrutide also met the study's second goal, helping patients at the highest dose lose an average of 16.8% of their weight, or 36.6 pounds, at 40 weeks, when evaluating only patients who stayed on the drug. When analyzing all participants, including those who discontinued treatment, the highest dose of the drug helped patients lose 15.3% of their weight. The company was also "very pleased" with the relatively low discontinuation rates due to side effects, which were up to 5%, he added. But Lilly has yet to file for approval of the drug for obesity or diabetes. The company expects to report findings from seven additional phase three trials on the drug by the end of the year. Still, retatrutide's A1C reduction doesn't appear to be the greatest Lilly has seen within its portfolio: The highest dose of Zepbound lowered the measure by more than 2% at 40 weeks in two separate trials on diabetes patients. Dubbed the "triple G" drug, retatrutide works by mimicking three hunger-regulating hormones – GLP-1, GIP and glucagon – rather than just one or two like existing treatments. That appears to have more potent effects on a person's appetite and satisfaction with food than other treatments. https://www.cnbc.com/2026/03/19/eli-lillys-obesity-drug-retatrutide-clears-late-stage-diabetes-trial.html XX The MiniMed Flex gets FDA approval. Thi is a new design from the company formerly known as Medtronic. It's about half the size* of the MiniMed™ 780G pump, no screen – smartphone controlled – and has the SmartGuard™ algorithm with Meal Detection™ technolog. At commercial launch, MiniMed Flex™ will support the company's newest sensor portfolio, including Simplera Sync™ sensor and the Instinct sensor, made by Abbott. MiniMed also announced the MiniMed™ Forward Program, which allows customers who start on the MiniMed™ 780G system to upgrade to the MiniMed Flex™ system for $0. MiniMed Flex™ is cleared for individuals ages 7 and older with type 1 diabetes, and for individuals 18 years and older with insulin-requiring type 2 diabetes. https://www.prnewswire.com/news-releases/minimed-announces-fda-clearance-of-minimed-flex-the-companys-smallest-insulin-pump-featuring-its-first-smartphone-controlled-design-302716864.html XX Lots of new out of the recent ATTD conference.. some headlines: New study from the UK shows that Ketone Monitoring Could Significantly Reduce DKA Risks in people with type 1 and type 2. This was a study by Abbott which recently submitted a continuous dual glucose-ketone monitor to the FDA for clearance – if approved, it could be available in the U.S. later this year. -- The first modified insulin producing cells are still working 14 months after transplant – without the need for immunosuppressive drugs. This is from Sana which now plans a study of a new therapy.. same gene-editing strategy with lab-grown, stem-cell-derived insulin-producing cells. -- Protein looks like it helps avoid lows during exercise. Both high and low doses of whey protein before exercise were effective, significantly reducing the risk of hypoglycemia by five to 10 times. Researchers noted that the body's response to protein was rapid (within 20 minutes), which suggests taking it close to the beginning of exercise could be beneficial for preventing hypoglycemia. Though more research is needed, there was also evidence showing protein intake could be beneficial for prolonged fasting and preventing overnight lows. -- More info about type 1 and GLP medications. Researchers at ATTD presented the results of a small, seven-month study assessing the effectiveness of semaglutide for people with type 1 diabetes and obesity. During the trial, 36% of participants taking semaglutide spent more than 70% of their time in range, less than 4% of their time below range, and lost more than 5% of their body weight compared to those not taking semaglutide. Treatment with semaglutide was also associated with reductions in cholesterol and blood pressure. Based on all of these changes, the researchers calculated that the participants who received semaglutide had significantly reduced their risk of heart disease over the next 10 years. Other studies show that since 2020, prescriptions of GLP-1 medications have grown exponentially for adults with type 1 diabetes between the ages of 18 and 85. https://diatribe.org/diabetes-research/top-diabetes-news-attd-2026 XX Lots of talk about fully closed loops.. CamDiab unveiled theirs.. called Liberty.. which the company says it's the world's first fully closed loop commercial launch. CamDiab offers the FDA-approved mylife CamAPS FX app for automating insulin delivery in MyLife's (formerly Ypsomed Diabetes Care's) insulin delivery pumps. The mylife CamAPS FX on iOS has full compatibility with leading continuous glucose monitors (CGMs). Those include the FreeStyle Libre 3 and Libre 3 Plus from Abbott and the Dexcom G6 so customers can use their preferred device. https://www.drugdeliverybusiness.com/camdiab-unveils-fully-closed-loop-insulin-feature/ XX Insulet reported data on a fully closed-loop automated insulin delivery system in people with Type 2 diabetes. The 24 people in the trial spent 24% more time in the target blood glucose range using the system than when receiving standard injection therapy. Insulet plans to start a pivotal study this year and aims to launch in 2028. Rival insulin pump manufacturer Tandem is on a similar course. Tandem CEO John Sheridan told investors on an earnings call last month that his team plans to start a pivotal trial this year to support a filing with the Food and Drug Administration in 2027. Medtronic disclosed the start of a pivotal trial of its Vivera fully closed-loop algorithm last month, shortly before spinning off the program as part of the MiniMed initial public offering. The algorithm, which is designed to eliminate carb counting and manual food bolusing, achieved a mean time in range of 73.8% without manual user input in a feasibility study. https://www.medtechdive.com/news/insulet-posts-clinical-data-on-fully-closed-loop-insulin-delivery-system/814516/ XX Congrats to all honored by the 2026 National Scientific and Health Care Achievement Awards from the American Diabetes Association! Shout out to Diana Isaacs, PharmD, BCACP, BC-ADM, CDCES: 2026 Outstanding Educator in Diabetes Award and to Korey Hood who receives the Richard Rubin award. Dr. Rubin was a pioneer in behavioral science and committed to keeping the person with diabetes at the center of research and care.
GLP‑1 receptor agonists continue to generate clinical and media buzz, with new formulations, new approvals, and expanding areas of research. This course explores key updates, including the FDA approval of the first oral GLP‑1 for chronic weight management and ongoing investigations into GLP‑1 therapies for conditions beyond diabetes and obesity. You will gain a timely overview of recent developments in GLP‑1s and how pharmacists can anticipate and support their evolving role in patient care.HOSTRachel Maynard, PharmDGameChangers Podcast Host and Clinical Editor, CEimpactLead Editor, PyrlsGUESTChristine Schumacher, PharmD, BCPS, BCACP, BCCP, BC-ADM, CDCES, FCCPProfessor, Pharmacy Practice and Clinical PharmacistMidwestern University Pharmacists, REDEEM YOUR CPE HERE!CPE is available to Health Mart franchise members onlyTo learn more about Health Mart, click here: https://join.healthmart.com/PRACTICE RESOURCEReceive the exclusive Practice Resource to use as a reference guide for this episode by enrolling in the course. Click here to enroll!CPE INFORMATIONLearning ObjectivesUpon successful completion of this knowledge-based activity, participants should be able to:1. Summarize recent regulatory and clinical updates related to GLP‑1 receptor agonists, including new formulations.2. Describe emerging areas of research into the use of GLP‑1 therapies beyond diabetes and obesity treatment.Rachel Maynard has no relevant financial relationships with ineligible companies to disclose. Christie Schumacher is a speaker for and is on the advisory board for Abbott. All relevant financial relationships have been mitigated.0.1 CEU/1.0 HrUAN: 0107-0000-26-081-H01-PInitial release date: 3/9/2026Expiration date: 3/9/2027Additional CPE details can be found here.
GLP‑1 receptor agonists continue to generate clinical and media buzz, with new formulations, new approvals, and expanding areas of research. This course explores key updates, including the FDA approval of the first oral GLP‑1 for chronic weight management and ongoing investigations into GLP‑1 therapies for conditions beyond diabetes and obesity. You will gain a timely overview of recent developments in GLP‑1s and how pharmacists can anticipate and support their evolving role in patient care.HOSTRachel Maynard, PharmDGameChangers Podcast Host and Clinical Editor, CEimpactLead Editor, PyrlsGUESTChristine Schumacher, PharmD, BCPS, BCACP, BCCP, BC-ADM, CDCES, FCCPProfessor, Pharmacy Practice and Clinical PharmacistMidwestern UniversityGET CE FOR THIS LISTENING!The GameChangers Clinical Update Series for Pharmacists delivers 52 expert-led podcast episodes and 30+ hours of clinically actionable continuing education, all for a one-time purchase of just $99—that's less than $3 per hour for high-impact learning you can apply immediately in practice. Click here to enroll. PRACTICE RESOURCEReceive the exclusive Practice Resource to use as a reference guide for this episode by purchasing the GameChangers Clinical Update Series. CPE REDEMPTIONThis course is accredited for continuing pharmacy education! Click the link below that applies to you to take the exam and evaluation to claim credit:If you are already enrolled in this course, click here to redeem your credit. To purchase the Clinical Update Series and claim your CPE credit, click here or to purchase this course individually, click here. CPE INFORMATIONLearning ObjectivesUpon successful completion of this knowledge-based activity, participants should be able to:1. Summarize recent regulatory and clinical updates related to GLP‑1 receptor agonists, including new formulations.2. Describe emerging areas of research into the use of GLP‑1 therapies beyond diabetes and obesity treatment.Rachel Maynard has no relevant financial relationships with ineligible companies to disclose. Christie Schumacher is a speaker for and is on the advisory board for Abbott. All relevant financial relationships have been mitigated.0.1 CEU/1.0 HrUAN: 0107-0000-26-081-H01-PInitial release date: 3/9/2026Expiration date: 3/9/2027Additional CPE details can be found here.Follow CEimpact on Social Media:LinkedInInstagram
In this first episode for 2026, Host Kerri Musselman, PharmD, BCACP, introduces Ashley Ramer, MSN, RN, to discuss the launch of EQUIPP Academy, a new educational platform designed to help pharmacy teams navigate value-based care and non-dispensing revenue opportunities. The conversation focuses on making clinical education accessible for busy pharmacy staff without interrupting patient care. EQUIPP Academy is structured around "micro-learning" modules. Most lessons are 5 minutes or less, allowing staff to gain essential knowledge on-demand during small gaps in their schedule.Who Should Participate: The academy is designed for all pharmacy team members, from new hires to seasoned staff, who handle EQUIPP data or patient outreach.Your pharmacy team can get started at https://equippacademy.com/
The American Diabetes Association's 2026 Standards of Care in Diabetes are here! Let's talk about what's changed and how to better care for our older adults living with diabetes. 2026 Standards of Care in Diabetes: https://diabetesjournals.org/care/issue/49/Supplement_1 Tamara Ruggles, PharmD, BCGP, FASCP: www.linkedin.com/in/tamara-ruggles-491882251 Diana Isaacs, PharmD, BCPS, BCACP, BC-ADM, CDCES: https://www.linkedin.com/in/diana-isaacs-pharmd-bcps-bcacp-bc-adm-cdces-45803426/
In this month's podcast episode, The Standards, hosts Neil Skolnik, MD, and Sara Wettergreen, PharmD, BCACP, BC-ADM, explain the Standards of Care in Diabetes from the American Diabetes Association® in clear, plain terms. This conversation is designed to help you better understand the guidance that shapes diabetes and obesity care. Presented by: Neil Skolnik, MD, Professor of Family and Community Medicine, Sidney Kimmel Medical College, Thomas Jefferson University; Associate Director, Family Medicine Residency Program, Abington Jefferson Health, Abington, PA Sara Wettergreen, PharmD, BCACP, BC-ADM, Assistant Professor, Department of Clinical Pharmacy, University of Colorado Skaggs School of Pharmacy and Pharmaceutical Sciences; and Ambulatory Care Clinical Pharmacist, UCHealth Lone Tree Primary Care, Aurora, CO Do you have questions or comments you'd like to share with Neil and Sara? Leave a message at (703) 755-7288. Thank you for listening, and don't forget to "follow" Diabetes Day by Day! Additional resources: Access the Standards of Care in Diabetes—2026 Access sections 1-3 of the Standards of Care in Overweight and Obesity Access Your Rights and Care Standards: A Guide for People with Type 2 Diabetes
Meagan Brown, PharmD, BCACP, joined Over the Counter to celebrate National Pharmacist Day and discuss the various avenues for expanding pharmacists' scope.
In this episode, Liz Unruh is joined by Kelly Eagan, PharmD, BCPS, BCACP, CDCES, the lead clinical pharmacist at Riverside's Cardiology Pharmacotherapy Clinic (CPC). Discover how clinical pharmacists play a crucial role in patient care management, help manage chronic conditions, and optimize medication therapy to ensure best outcomes for patients. Tune in to understand the unique value they bring to the healthcare team!
Discover the essential contributions of pharmacists in patient care with We're Your Pharmacist, a monthly podcast from ASHP. This episode features Jennifer Slaughter, ambulatory pharmacy supervisor at SSM Health Dean Medical Group, and her patient Debbie. Jennifer shares what inspired her to pursue a career in pharmacy and discusses the many paths within the profession, while Debbie offers her perspective as a patient and shares insights on the value of the pharmacist–patient relationship. The information presented during the podcast reflects solely the opinions of the presenter. The information and materials are not, and are not intended as, a comprehensive source of drug information on this topic. The contents of the podcast have not been reviewed by ASHP, and should neither be interpreted as the official policies of ASHP, nor an endorsement of any product(s), nor should they be considered as a substitute for the professional judgment of the pharmacist or physician.
In this episode of Diabetes Day by Day, Drs. Neil Skolnik and Sara Wettergreen are joined by Aaron Sutton, LCSW, BCD, CAADC, to explore the unique challenges the holidays can bring when living with diabetes. They share practical strategies and offer guidance on how loved ones can provide meaningful support throughout the holiday season. Presented by: Neil Skolnik, MD, Professor of Family and Community Medicine, Sidney Kimmel Medical College, Thomas Jefferson University; Associate Director, Family Medicine Residency Program, Abington Jefferson Health, Abington, PA Sara Wettergreen, PharmD, BCACP, BC-ADM, Assistant Professor, Department of Clinical Pharmacy, University of Colorado Skaggs School of Pharmacy and Pharmaceutical Sciences; and Ambulatory Care Clinical Pharmacist, UCHealth Lone Tree Primary Care, Aurora, CO Aaron Sutton, LCSW, BCD, CAADC, Director of the Sutton Institute for Psychotherapy Do you have questions or comments you'd like to share with Neil and Sara? Leave a message at (703) 755-7288. Thank you for listening, and don't forget to "follow" Diabetes Day by Day!
This is the 13th episode in my Pharmacist Podcasters Series. My guests and I talk about podcasting to inspire you to start your own podcast, be a podcast guest, or use your voice in general. If you're interested in podcasting, pod-guesting or public speaking, you need to listen to this episode (and the Series!). My guest today is Dr. Brooke Griffin, host of the 5 Minute Pep Talk Podcast. If you need a short, motivational podcast with a positive vibe that gets to the point quickly, subscribe to or follow The 5 Minute Pep Talk today. Click to read the FULL show notes: https://www.thepharmacistsvoice.com/podcast (select episode 357) Background information for Brooke Griffin, PharmD (October 2025) Brooke Griffin, PharmD, BCACP is a Professor of Pharmacy Practice and Vice Chair of Clinical Services at Midwestern University College of Pharmacy. She is a Professional Coach in Life & Work and is passionate about offering career support through a thought-provoking and creative process. In 2022 she launched Bold Idea Group with a mission to inspire bold ideas from within. She loves providing a positive space in our profession while acknowledging that it's a roller coaster of excitement and stress. For coaching tools, inspiration, and to learn more about Brooke, listen to her 5-minute podcast, "5 Minute Pep Talk." She is on this self-development journey alongside all of you and believes "every pharmacist deserves a coach." Share this episode! If you know someone who might like this episode, please share this episode with them. Subscribe to or follow The Pharmacist's Voice ® Podcast on your favorite podcast player and YouTube to get each new episode when it comes out. Popular links are below. Apple Podcasts https://apple.co/42yqXOG Spotify https://spoti.fi/3qAk3uY Amazon/Audible https://adbl.co/43tM45P YouTube https://bit.ly/43Rnrjt If you need help starting your podcast, I can help. I coach students one-on-one, sell a self-paced online course, and sell a book about podcast planning. Get my book in print, eBook, or audiobook on amazon.com. You can also listen to the episodes about podcasting in my back catalog on thepharmacistsvoice.com/podcast. Links from this episode Follow the 5 Minute Pep Talk on your favorite podcast player https://rss.com/podcasts/todaysboldidea/?listen-on=true 5 Minute Pep Talk on Apple Podcasts https://podcasts.apple.com/us/podcast/5-minute-pep-talk-mindset-motivation-and-coaching-for/id1757538544 5 Minute Pep Talk on Spotify https://open.spotify.com/show/6CSKzhnuhQWy2HyImxN2fD Brooke on LinkedIn https://www.linkedin.com/in/brookegriffinpharmd/ Brooke's Free Private Facebook Group https://www.facebook.com/groups/boldideagroup Brooke's Business Website https://www.boldideagroup.com/ Big Magic: Creative Living Beyond Fear by Elizabeth Gilbert KNOWN: The Handbook for Building and Unleashing Your Personal Brand in the Digital Age by Mark W. Schaefer Building a StoryBrand: Clarify Your Message So Customers Will Listen by Donald Miller Pharmacist Podcaster: A Podcast Planning Guide for Pharmacy Professionals by Kim Newlove Pharmacist Podcasters Series Part 1 with Ola Latala, PharmD (The Pharmacist's Voice Podcast Episode 248) Part 2 with Deeb Eid, PharmD (The Pharmacist's Voice Podcast Episode 253) Part 3 with Justin Cole, PharmD (The Pharmacist's Voice Podcast Episode 257) Part 4 with Christina Fontana, PharmD The Pharmacist's Voice Podcast Episode 262 Part 5 with Tony Dao, PharmD The Pharmacist's Voice Podcast Episode 266 Part 6 with Dr. H (Hussam Hamoush, PharmD) The Pharmacist's Voice Podcast Episode 275 Part 7 with Julie Doan, PharmD The Pharmacist's Voice Podcast Episode 297 Part 8 with Tim Ulbrich, PharmD The Pharmacist's Voice Podcast Episode 306 Part 9 with Zain Syed, PharmD The Pharmacist's Voice Podcast Episode 310 Part 10 with Rachel Gainsbrugh, PharmD The Pharmacist's Voice Podcast Episode 323 Part 11 with Danielle Plummer, PharmD The Pharmacist's Voice Podcast Episode 329 Part 12 with Cory Jenks, PharmD The Pharmacist's Voice Podcast Episode 334 Kim's websites and social media links: ✅ Guest Application Form (The Pharmacist's Voice Podcast) https://bit.ly/41iGogX ✅ Monthly email newsletter sign-up link https://bit.ly/3AHJIaF ✅ LinkedIn Newsletter https://bit.ly/40VmV5B ✅ Business website https://www.thepharmacistsvoice.com ✅ The Pharmacist's Voice ® Podcast https://www.thepharmacistsvoice.com/podcast ✅ Pronounce Drug Names Like a Pro © Online Course https://www.kimnewlove.com ✅ Pharmacist Podcaster Book https://amzn.to/4iAKNBs ✅ Podcasting Online Course https://www.kimnewlove.com/podcasting ✅ Private Podcasting Coaching or Consulting https://www.kimnewlove.com/private-coaching ✅ LinkedIn https://www.linkedin.com/in/kimnewlove ✅ Facebook https://www.facebook.com/kim.newlove.96 ✅ Twitter https://twitter.com/KimNewloveVO ✅ Instagram https://www.instagram.com/kimnewlovevo/ ✅ YouTube https://www.youtube.com/channel/UCA3UyhNBi9CCqIMP8t1wRZQ ✅ ACX (Audiobook Narrator Profile) https://www.acx.com/narrator?p=A10FSORRTANJ4Z ✅ Start a podcast with the same coach who helped me get started (Dave Jackson from The School of Podcasting)! **Affiliate Link - NEW 9-8-23** Thank you for listening to episode 357 of The Pharmacist's Voice ® Podcast. If you know someone who would like this episode, please share it with them!
In this episode of Diabetes Day by Day, Drs. Neil Skolnik and Sara Wettergreen talk with Dr. Akturk about the potential health risks associated with cannabis use for people living with diabetes. Cannabis use can affect blood glucose management, heart health, and even how someone manages their medications. Understanding the risks of cannabis use is an important part of managing diabetes safely. Staying informed and having open conversations with your health care team are the best ways to protect your health. Presented by: Neil Skolnik, MD, Professor of Family and Community Medicine, Sidney Kimmel Medical College, Thomas Jefferson University; Associate Director, Family Medicine Residency Program, Abington Jefferson Health, Abington, PA Sara Wettergreen, PharmD, BCACP, BC-ADM, Assistant Professor, Department of Clinical Pharmacy, University of Colorado Skaggs School of Pharmacy and Pharmaceutical Sciences; and Ambulatory Care Clinical Pharmacist, UCHealth Lone Tree Primary Care, Aurora, CO Halis Kaan Akturk, MD, Associate Professor of Medicine and Pediatrics, Barbara Davis Center for Diabetes, University of Colorado, Aurora, CO Do you have questions or comments you'd like to share with Neil and Sara? Leave a message at (703) 755-7288. Thank you for listening, and don't forget to "follow" Diabetes Day by Day!
Cardiovascular-kidney-metabolic (CKM) syndrome is progressive, but can be halted or even reversed with effective management. Guests Chiai Ndumele, MD, PhD, and Joe Saseen, PharmD, BCPS, BCACP, describe the role of inflammation and how the biologic factors for diagnosis and treatment are nested within a patient's social context.2023 AHA Statement Cardiovascular-Kidney-Metabolic Health: https://www.ahajournals.org/doi/10.1161/cir.0000000000001184 Related Resources:PCNA CKM tools and resources: https://pcna.net/resources/patient-education/patient-information/cardiovascular-kidney-metabolic-syndrome-resources/ AHA Cardiovascular Kidney Metabolic Health Presidential Advisory: https://professional.heart.org/en/science-news/cardiovascular-kidney-metabolic-health-a-presidential-advisoryAHA CKM Syndrome Implementation Guide: https://www.heart.org/en/professional/cardiovascular-kidney-metabolic-health/implementationPCNA CKM Resource list: https://pcna.net/resources/patient-education/patient-information/cardiovascular-kidney-metabolic-syndrome-resources/See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.
Discover the essential contributions of pharmacists in patient care with We're Your Pharmacist, a monthly podcast from ASHP. This episode features Amber Lanae Martirosov, associate clinical professor of pharmacy practice at Wayne State University and clinical specialist at Henry Ford Hospital. She shares what inspired her to pursue a career in pharmacy and offers insights into the many paths within the profession, highlighting how pharmacists make a difference every day. The information presented during the podcast reflects solely the opinions of the presenter. The information and materials are not, and are not intended as, a comprehensive source of drug information on this topic. The contents of the podcast have not been reviewed by ASHP, and should neither be interpreted as the official policies of ASHP, nor an endorsement of any product(s), nor should they be considered as a substitute for the professional judgment of the pharmacist or physician.
In this episode of Diabetes Day by Day, Drs. Neil Skolnik and Sara Wettergreen talk with Aaron Sutton, LCSW, BCD, CAADC, and Casey Coffman about decision fatigue—what it means and ways to cope, especially as the holiday season approaches. Living with diabetes means making countless decisions every day—from meal choices to medication timing. Over time, this can lead to decision fatigue, impacting both your mental health and diabetes management. Presented by: Neil Skolnik, MD, Professor of Family and Community Medicine, Sidney Kimmel Medical College, Thomas Jefferson University; Associate Director, Family Medicine Residency Program, Abington Jefferson Health, Abington, PA Sara Wettergreen, PharmD, BCACP, BC-ADM, Assistant Professor, Department of Clinical Pharmacy, University of Colorado Skaggs School of Pharmacy and Pharmaceutical Sciences; and Ambulatory Care Clinical Pharmacist, UCHealth Lone Tree Primary Care, Aurora, CO Aaron Sutton, LCSW, BCD, CAADC, Director of the Sutton Institute for Psychotherapy Casey Coffman, American Diabetes Association® volunteer and a person living with type 1 diabetes Do you have questions or comments you'd like to share with Neil and Sara? Leave a message at (703) 755-7288. Thank you for listening, and don't forget to "follow" Diabetes Day by Day!
Brad Phillips, PharmD, BCACP, joined Over the Counter during American Pharmacists Month to discuss the evolution of pharmacy education amid a rapidly growing expansion of pharmacists' clinical authority.
ASHP's education director, Hannah Post is joined by Angela Cassano, president of Pharmfusion Consulting, LLC, William Hammonds, clinical pharmacy manager at West Virginia University Medicine, and Carrington Huneycutt, director of clinical pharmacy at Tandem Health, South Carolina, as they discuss their upcoming Midyear session that focuses on implementation and evolution of clinical pharmacy technician roles. The information presented during the podcast reflects solely the opinions of the presenter. The information and materials are not, and are not intended as, a comprehensive source of drug information on this topic. The contents of the podcast have not been reviewed by ASHP, and should neither be interpreted as the official policies of ASHP, nor an endorsement of any product(s), nor should they be considered as a substitute for the professional judgment of the pharmacist or physician.
Note from our guest: We are seeking your participation in a survey about pediatric vaccines BEFORE you listen to the podcast. The survey should take no longer than 5-10 minutes to complete. Survey results will be used to identify potential reasons for hesitancy when it comes to pediatric vaccines.Participation in the survey is voluntary. Participants will not encounter any costs. Pre survey: https://uofmississippi.qualtrics.com/jfe/form/SV_etgBsnrF9FJdgCaAfter listening to the podcast there is a separate survey to enter into a randomized drawing for one of ten $20 amazon gift cards. Survey expires towards the end of October 2025. Post survey: https://uofmississippi.qualtrics.com/jfe/form/SV_b7a5yDmONTpKn2KEmail the show at kids@mpbonline.orgHost: Dr. Morgan McLeod, Asst. Professor of Pediatrics and Internal Medicine at the University of Mississippi Medical Center.If you enjoyed listening to this podcast, please consider contributing to MPB: https://donate.mpbfoundation.org/mspb/podcastGuest: Ha Phan, PharmD, CDCES, BCACP (she/her/hers)Clinical Associate Professor of Pharmacy PracticePGY2 Ambulatory Care Pharmacy Residency Program Directorwebsite mentioned: The Children's Hospital of Philadelphia - vaccine ingredients Hosted on Acast. See acast.com/privacy for more information.
Join Drs. Neil Skolnik and Sara Wettergreen as they answer one of the most common questions people living with diabetes have: “What diabetes medication is best for me?” In this episode, they'll explore how choosing the right medication depends on your individual health, lifestyle, and goals. Discover practical tips to better help you work with your care team to make informed decisions and find the best treatment plan for you. Presented by: Neil Skolnik, MD, Professor of Family and Community Medicine, Sidney Kimmel Medical College, Thomas Jefferson University; Associate Director, Family Medicine Residency Program, Abington Jefferson Health, Abington, PA Sara Wettergreen, PharmD, BCACP, BC-ADM, Assistant Professor, Department of Clinical Pharmacy, University of Colorado Skaggs School of Pharmacy and Pharmaceutical Sciences; and Ambulatory Care Clinical Pharmacist, UCHealth Lone Tree Primary Care, Aurora, CO Do you have questions or comments you'd like to share with Neil and Sara? Leave a message at (703) 755-7288. Thank you for listening, and don't forget to “follow” Diabetes Day by Day! Diabetes Medications: Biguanides Brand: Glucophage, Fortamet, Glumetza Generic: Metformin, Metformin XR Sulfonylureas (Second Generation) Brand: Glucotrol, Amaryl, Diaβeta, Glynase Generic: Glipizide, Glipizide XL, Glimepiride, Glyburide Thiazolidinediones (TZDs) Brand: Actos, Avandia Generic: Pioglitazone, Rosiglitazone (no longer available) DPP-4 Inhibitors Brand: Januvia, Onglyza, Tradjenta, Nesina Generic: Sitagliptin, Saxagliptin, Linagliptin, Alogliptin SGLT2 Inhibitors Brand: Invokana, Farxiga, Jardiance, Steglatro, Brenzavvy Generic: Canagliflozin, Dapagliflozin, Empagliflozin, Ertugliflozin, Bexagliflozin GLP-1 Receptor Agonists Brand: Victoza, Trulicity, Ozempic, Rybelsus, Mounjaro (dual GIP/GLP-1) Generic: Liraglutide, Dulaglutide, Semaglutide, Tirzepatide Insulins (selected examples) Brand: Humalog, NovoLog, Apidra, Lantus, Basaglar, Levemir, Tresiba, Humulin N, Novolin N, Humulin R, Novolin R Generic: Insulin lispro, Insulin aspart, Insulin glulisine, Insulin glargine, Insulin detemir, Insulin degludec, NPH insulin, Regular insulin
Celebrate the American Diabetes Association®'s (ADA) 85th anniversary with Drs. Neil Skolnik and Sara Wettergreen, joined by Dr. Marlon Pragnell, Charlene Wallace, and Stacey Krawczyk. Together, they'll reflect on the ADA's legacy of groundbreaking research and how it continues to shape the programs and resources available today. The conversation will also highlight practical tools—from nutrition guidance to the National Diabetes Prevention Program—to support you and your loved ones in managing or preventing diabetes. Because it all matters. Presented by: Neil Skolnik, MD, Professor of Family and Community Medicine, Sidney Kimmel Medical College, Thomas Jefferson University; Associate Director, Family Medicine Residency Program, Abington Jefferson Health, Abington, PA Sara Wettergreen, PharmD, BCACP, BC-ADM, Assistant Professor, Department of Clinical Pharmacy, University of Colorado Skaggs School of Pharmacy and Pharmaceutical Sciences; and Ambulatory Care Clinical Pharmacist, UCHealth Lone Tree Primary Care, Aurora, CO Marlon Pragnell, PhD, Vice President of Research and Science at the ADA Charlene Wallace, MBA, Vice President of Diabetes Prevention at the ADA Stacey Krawczyk, MS, RD, Director of Nutrition and Wellness at the ADA Do you have questions or comments you'd like to share with Neil and Sara? Leave a message at (703) 755-7288. Thank you for listening, and don't forget to “follow” Diabetes Day by Day! Additional resources: Research Impact Learn More About the National Diabetes Prevention Program Eating for Diabetes Management Diabetes Food Hub More on the ADA's 85th Anniversary
ASHP's senior education director, Cindy Von Heeringen is joined by Angela Goodhart, associate professor of Clinical Pharmacy and Family Medicine at West Virginia University, as she discusses her upcoming Midyear sessions that focuses on key components for a successful residency interview and defining characteristics and values of the different generations. The information presented during the podcast reflects solely the opinions of the presenter. The information and materials are not, and are not intended as, a comprehensive source of drug information on this topic. The contents of the podcast have not been reviewed by ASHP, and should neither be interpreted as the official policies of ASHP, nor an endorsement of any product(s), nor should they be considered as a substitute for the professional judgment of the pharmacist or physician.
Stream this podcast to learn from experts Alexis E. Horace, PharmD, BCACP,andNimish Patel, PharmD, PhD, AAHIVP, how specialist pharmacists can overcome key barriers to care and apply best practices for optimization of antiretroviral therapy for HIV. Topics covered include: Leveraging pharmacists' expertise to advance HIV treatmentPharmacist roles in HIV care and management The current ART landscapeRegimen simplificationConsideration of patient preferences, health factors, and comorbidities for ART optimizationART management for treatment-experienced patients, including those with multidrug-resistant HIVPresenters:Alexis E. Horace, PharmD, BCACPProfessor of Pharmacy PracticeUniversity of Louisiana at Monroe College of PharmacyNew Orleans CampusCrescentCare Ambulatory Care Clinical Pharmacist, HIV SpecialtyNew Orleans, LouisianaNimish Patel, PharmD, PhD, AAHIVPProfessor of Clinical PharmacyDivision of Clinical PharmacySkaggs School of Pharmacy & Pharmaceutical SciencesUniversity of California, San DiegoLa Jolla, CaliforniaLink to full program: https://bit.ly/41agtqQGet access to all of our new podcasts by subscribing to the CCO Infectious Disease Podcast on Apple Podcasts, Google Podcasts, or Spotify.
Artificial intelligence (AI) will bring many opportunities to the pharmacy profession, but it can be tempting to use AI in place of critical thinking or reliable research around drug information questions (DIQs). One must wonder, will the pharmacist be held liable if AI gets it wrong? Guest Authors: Elizabeth B. Hearn, PharmD, BCACP, CDCES; Karlyn E. Hood, PharmD, BCPS; Abigail L. Torres, PharmD Music by Good Talk
© 2020-2026 Ivy Podcast Discovery LLC
